Ideaya Biosciences announced that the FDA has granted Fast Track designation to Ideaya’s development program investigating IDE161, a potent and selective inhibitor of poly glycohydrolase, for the treatment of adult patients having advanced or metastatic ovarian cancer with germline or somatic BRCA 1/2 mutations who are platinum resistant and have received prior antiangiogenic and poly polymerase inhibitor therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IDYA:
- Ideaya Biosciences initiates monotherapy expansion in IDE161 trial
- Biotech Alert: Searches spiking for these stocks today
- Ideaya Biosciences announces FDA clearance of GSK101 IND application
- Ideaya Biosciences doses first patient in darovasertib trial
- Ideaya Biosciences price target raised to $40 from $35 at Wedbush